Sugi Predict

Sugi Predict / Compounds / SCHEMBL4195533

SCHEMBL4195533

SCHEMBL4195533

CC(=O)c1ccc(N[C@@H](C)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ LMNA P02545 2/20 0.59
▸ MAPT P10636 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ RAB9A P51151 4/20 0.50
▸ NPC1 O15118 3/20 0.50
▸ TAAR1 Q96RJ0 1/20 0.50
▸ MAPK1 P28482 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ HTT P42858 1/20 0.44
▸ NLRP1 Q9C000 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ AKR1C3 P42330 1/20 0.44
▸ AKR1C2 P52895 1/20 0.44
▸ CYP1A1 P04798 1/20 0.43
▸ CYP1B1 Q16678 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4195531 1.00 KMT2A (0.59) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL350279 0.86 TP53 (0.48) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL6237516 0.86 TP53 (0.48) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL350280 0.86 TP53 (0.48) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL1485846 0.83 LMNA (0.43) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL27999259 0.83 POLB (0.48) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL10055051 0.82 RXFP1 (0.56) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL11197363 0.81 MEN1 (0.51) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL669563 0.81 MAPK13 (0.61) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL11056637 0.81 MEN1 (0.51) KMT2AMEN1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689127-A1 RF1 KO E. COLI STRAINS Sutro Biopharma, Inc. (US) 2026-02-11 — — EP disclosed
US-20250108048-A1 STING AGONIST COMPOUNDS AND CONJUGATES SUTRO BIOPHARMA, INC. 2025-04-03 — — US disclosed
WO-2025029832-A2 STING AGONIST COMPOUNDS AND CONJUGATES SUTRO BIOPHARMA, INC. (US) 2025-02-06 — — WO disclosed
US-12180552-B2 Site-specific conjugation of linker drugs to antibodies and resulting ADCs BYONDIS B.V. (NL) 2024-12-31 — — US disclosed
WO-2024211306-A1 RF1 KO E. COLI STRAINS SUTRO BIOPHARMA, INC. (US) 2024-10-10 — — WO disclosed
CN-106456794-B Site-specific conjugation of linker drugs to antibodies and the resulting ADCs 拜奥迪斯私人有限公司 2023-02-17 — — CN disclosed
EP-4117732-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF Ambrx, Inc. (US) 2023-01-18 — — EP disclosed
US-20210388115-A1 SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS BYONDIS BV (NL) 2021-12-16 — — US disclosed
US-11136633-B2 Site-specific conjugation of linker drugs to antibodies and resulting ADCS BYONDIS B.V. (NL) 2021-10-05 — — US disclosed
WO-2021183832-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF AMBRX, INC. (US) 2021-09-16 — — WO disclosed
EP-3849592-A1 MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES Exalt Therapeutics, LLC (US) 2021-07-21 — — EP disclosed
WO-2020041636-A1 MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES EXALT THERAPEUTICS, LLC (US) 2020-02-27 — — WO disclosed
EP-3539544-A1 SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS Synthon Biopharmaceuticals B.V. (NL) 2019-09-18 — — EP disclosed
EP-3151865-A1 SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS Synthon Biopharmaceuticals B.V. (NL) 2017-04-12 — — EP disclosed
EP-2968552-A1 TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF The California Institute for Biomedical Research (US) 2016-01-20 — — EP disclosed
WO-2015177360-A1 SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS SYNTHON BIOPHARMACEUTICALS B.V. (NL) 2015-11-26 — — WO disclosed
WO-2014153164-A1 TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-09-25 — — WO disclosed
EP-1974025-A4 NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY AMBRX INC (US) 2009-03-11 — — EP disclosed
EP-1974025-A2 NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY Ambrx, Inc. (US) 2008-10-01 — — EP disclosed
WO-2007094916-A2 NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY AMBRX, INC. (US) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136633-B2 Site-specific conjugation of linker drugs to antibodies and resulting ADCS MCL1, CD44, GLS2 KMT2A 130/4885MEN1 246/4885LMNA 4492/4885
US-12180552-B2 Site-specific conjugation of linker drugs to antibodies and resulting ADCs MCL1, CD44, GLS2 KMT2A 130/4885MEN1 246/4885LMNA 4492/4885
US-20250108048-A1 STING AGONIST COMPOUNDS AND CONJUGATES STING1, CGAS, MAVS KMT2A 3278/4885MEN1 2370/4885LMNA 2064/4885
US-20210388115-A1 SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS MCL1, CD44, GLS2 KMT2A 130/4885MEN1 246/4885LMNA 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.